Search | Clinical Trials Finder

Conditions: Glaucoma, Ocular Hypertension
Interventions: Bimatoprost 0.01% ophthalmic solution, Bimatoprost 0.015% formulation 1 ophthalmic solution, Bimatoprost 0.015% formulation 2 ophthalmic solution, Bimatoprost 0.02% ophthalmic solution, Bimatoprost 0.03% ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Wenatchee, Washington

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost (SR); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 38
States / cities: Sun City, Arizona • Huntington Beach, California • Irvine, California + 32 more

Conditions: Hypotrichosis
Interventions: bimatoprost ophthalmic solution 0.03%, bimatoprost vehicle solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Alopecia, Breast Cancer
Interventions: bimatoprost ophthalmic solution, placebo; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Ocular Hypertension, Primary Open-Angle Glaucoma
Interventions: AGN-210961 Formulation 1, AGN-210961 Formulation 2, AGN-210961 Formulation 3, AGN-210961 Formulation 4, AGN-210961 Formulation 5, AGN-210961 Formulation 6, AGN-210961 Formulation 7, bimatoprost ophthalmic solution 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma
Interventions: Latanoprost, Bimatoprost, Travoprost, Timolol, Dorzolamide, Brinzolamide, Acetazolamide, Methazolamide; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypotrichosis
Interventions: bimatoprost ophthalmic 0.03% solution, vehicle sterile solution (placebo); Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Eyelash Hypotrichosis
Interventions: bimatoprost ophthalmic solution 0.005%, bimatoprost ophthalmic solution 0.015%, bimatoprost ophthalmic solution 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 30 Years to 55 Years · Female only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost; Drug
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 6 more

Conditions: Ocular Hypertension
Interventions: bimatoprost/timolol fixed combination; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Bel Air, Maryland

Conditions: Cataract
Interventions: Bimatoprost 0.03%; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 4
States / cities: Indianapolis, Indiana

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost, Timolol 0.5%, Placebo Ocular Insert, Placebo Eye Drops; Drug · Device
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 10
States / cities: Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 7 more

Conditions: Glaucoma, Open-Angle Glaucoma, Ocular Hypertension, Glaucoma Suspect
Interventions: Durysta, Bimatoprost Intracameral Implant 10 µg; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: bimatoprost ophthalmic solution 0.01%, travoprost ophthalmic solution 0.004%, latanoprost ophthalmic solution 0.005%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rogers, Arkansas

Conditions: Healthy Volunteers
Interventions: Bimatoprost Ophthalmic; Drug
Lead sponsor: Laboratoires Thea; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Glaucoma
Interventions: Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cataract, Glaucoma, Ocular Hypertension
Interventions: Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL; Drug · Device
Lead sponsor: SpyGlass Pharma, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: AGN-210669 ophthalmic solution, 0.1%, AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, bimatoprost ophthalmic solution 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost; Drug
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Artesia, California • La Jolla, California • Newport Beach, California + 7 more

Conditions: Glaucoma, Open-Angle
Interventions: Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution); Drug
Lead sponsor: Mankind Pharma Limited; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: Bakersfield, California • Mission Hills, California • Newport Beach, California + 5 more

Conditions: Glaucoma, Application Site Pigmentation Changes
Interventions: latanoprost, bimatoprost, travoprost; Drug
Lead sponsor: Summa Health System; Other
Eligibility: 30 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Arlington Heights, Illinois • Akron, Ohio

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution); Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 9
States / cities: Newport Beach, California • Petaluma, California • New Smyrna Beach, Florida + 6 more

Conditions: Idiopathic Eyelash Hypotrichosis
Interventions: bimatoprost formulation A solution, bimatoprost solution 0.03 %, vehicle of bimatoprost formulation A solution, vehicle of bimatoprost solution 0.03 %; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Newport Beach, California

Search by objective public record fields.

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants

Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Stop Retinal Ganglion Cell Dysfunction Study

Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis

Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert

Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous.

Dose-Ranging Study of the Bimatoprost Ocular Insert

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

Bimatoprost in the Treatment of Eyelash Hypotrichosis